Literature DB >> 10776952

Feeding tolerance in premature infants fed fortified human milk.

G J Moody1, R J Schanler, C Lau, R J Shulman.   

Abstract

BACKGROUND: To evaluate feeding tolerance in premature infants immediately after the addition of human milk fortifier (HMF) to their expressed human milk diet.
METHODS: Data on milk intake, feeding tolerance, and related assessments and growth milestones from a prospective study of feeding strategies in premature infants were analyzed. The database was searched for the first day HMF was added to the feeding of infants receiving human milk exclusively. The following assessments were tabulated for the 5 days before and the 5 days after the addition of HMF: milk intake, the number of episodes of abdominal distension, gastric residual volume (GRV) more than 2 ml/kg and more than 50% of the volume fed in the prior 3 hours. bile-stained gastric residual, emesis or regurgitation, blood in the stool, the number of abdominal radiographs, the number of episodes of apnea and bradycardia, changes in findings in the clinical examination, and the number of hours feeding was withheld. The time to achieve full tube feeding, complete oral feeding, and hospital discharge were recorded.
RESULTS: Seventy-six exclusively human milk-fed premature infants (birth weight, 1065+/-18 g; gestational age, 27+/-0.1 weeks; mean +/- SEM) who received HMF beginning 22+/-0.8 days of age were evaluated. There were significant increases in milk intake and in the number of episodes of GRV more than 2 ml/kg and emesis after the addition of HMF. There were no differences in the number of hours feeding was withheld or any other assessment after the addition of HMF. Infants with increases in GRV more than 2 ml/kg and/or emesis after the addition of HMF were not more likely to be delayed in the time to achieve full tube feeding, complete oral feeding, or hospital discharge than infants who did not experience these events.
CONCLUSION: These data suggest that, when all feeding and related assessments and the time to achieve important growth milestones are considered, the addition of HMF does not adversely affect the outcome of the premature infant.

Entities:  

Mesh:

Year:  2000        PMID: 10776952     DOI: 10.1097/00005176-200004000-00011

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Evaluation of potential factors predicting attainment of full gavage feedings in preterm infants.

Authors:  Robert J Shulman; Ching-Nan Ou; E O'Brian Smith
Journal:  Neonatology       Date:  2010-06-30       Impact factor: 4.035

2.  A national survey of the enteral feeding practices in Canadian neonatal intensive care units.

Authors:  James Haiyang Xu; Helen Coo; Sandra Fucile; Eugene Ng; Joseph Y Ting; Prakesh S Shah; Kimberly Dow
Journal:  Paediatr Child Health       Date:  2019-08-30       Impact factor: 2.253

3.  Growth and Bone Mineralization of Very Preterm Infants at Term Corrected Age in Relation to Different Nutritional Intakes in the Early Postnatal Period.

Authors:  Michelle N Körnmann; Viola Christmann; Charlotte J W Gradussen; Laura Rodwell; Martin Gotthardt; Johannes B Van Goudoever; Arno F J Van Heijst
Journal:  Nutrients       Date:  2017-12-02       Impact factor: 5.717

4.  Comparative study of preterm infants fed new and existing human milk fortifiers showed favourable markers of gastrointestinal status.

Authors:  Jacques Rigo; Jean-Michel Hascoët; Jean-Charles Picaud; Fabio Mosca; Amandine Rubio; Elie Saliba; Michaël Radkë; Umberto Simeoni; Bernard Guillois; Nicholas P Hays; Mickaël Hartweg; Claude Billeaud; Johannes Spalinger
Journal:  Acta Paediatr       Date:  2019-09-30       Impact factor: 2.299

5.  Human milk-based fortifier is associated with less alteration of milk fat globule size than cow milk-based fortifier.

Authors:  Yurika Yoshida; Minami Azuma; Haruhiro Kuwabara; Tokuo Miyazawa; Yuya Nakano; Kazuna Furukawa; Keli M Hawthorne; Masahiko Izumizaki; Takashi Takaki; Mari Sakaue; Katsumi Mizuno
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.